What question did this study set out to answer?

To evaluate and compare the hemodynamic dose-response effects and safety of intravenous versus oral acebutolol in patients presenting with acute myocardial infarction.

September 1, 1985Clinical Pharmacology & Therapeutics

Circulatory effects of intravenous and oral acebutolol in acute myocardial infarction

View Full Paper

Ask AI

Bookmark

Why the study?

Does intravenous or oral acebutolol alter hemodynamic variables in men with acute uncomplicated myocardial infarction?

Key Points

To evaluate and compare the hemodynamic dose-response effects and safety of intravenous versus oral acebutolol in patients presenting with acute myocardial infarction.
Conducted a randomized between-group study of 24 men (n=6 per group) within 17 hours of an acute uncomplicated myocardial infarction.
Administered intravenous acebutolol (25 or 50 mg) or oral acebutolol (200 or 400 mg) after a 1-hour control period.
Measured hemodynamic variables and plasma drug concentrations at 15 (intravenous only), 30, 60, 90, 120, and 240 minutes post-dose.
No clear hemodynamic dose-response effects were observed within the tested dose ranges for either intravenous or oral administration.
Acebutolol consistently reduced systolic and mean arterial pressure, heart rate, stroke volume, and cardiac output across all groups, while transiently increasing systemic vascular resistance and pulmonary artery occluded pressure.
Maximum hemodynamic changes occurred within 15–30 minutes after intravenous dosing (lasting 2 hours) and within 1–2 hours after oral dosing (lasting 4 hours), with oral dosing producing a significant cardiac output reduction (-0.7 L/min/m², P < 0.05) by 30 minutes.

Structured PICO

Does intravenous or oral acebutolol alter hemodynamic variables in men with acute uncomplicated myocardial infarction?

Population

24 men within 17 hours of an acute uncomplicated myocardial infarction

Intervention

Acebutolol administered intravenously (25 mg or 50 mg) or orally (200 mg or 400 mg)

Comparator

Between-group comparison of different doses and routes of acebutolol (IV 25 mg, IV 50 mg, oral 200 mg, oral 400 mg)

Outcome

Hemodynamic variables (systolic and mean systemic arterial pressure, heart rate, cardiac output, stroke volume, pulmonary artery occluded pressure, systemic vascular resistance) and plasma drug concentrations measured up to 240 minutes after dosingsurrogate

Both intravenous and oral acebutolol demonstrate hemodynamic safety in the early phase of acute uncomplicated myocardial infarction, with distinct time-dependent effects based on the route of administration.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports hemodynamic safety of early acebutolol in uncomplicated acute MI; extends route-specific timing data for beta-blocker use.

Cite This Study

Silke et al. (1985) studied this question.

synapsesocial.com/papers/6a7d38baff1a536db837d3c8 https://doi.org/10.1038/clpt.1985.169

View Full Paper

Ask AI

Bookmark

Circulatory effects of intravenous and oral acebutolol in acute myocardial infarction

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Circulatory effects of intravenous and oral acebutolol in acute myocardial infarction

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider